Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Bibliographic Details
Main Author:	Applied Bionics and Biomechanics
Format:	Article
Language:	English
Published:	Hindawi Limited 2023-01-01
Series:	Applied Bionics and Biomechanics
Online Access:	http://dx.doi.org/10.1155/2023/9813798

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
by: Man Yao, et al.
Published: (2022-01-01)

DEB‐TACE versus cTACE for unresectable HCC with B1‐type bile duct invasion after successful biliary drainage: A propensity score matching analysis
by: Wenzhe Fan, et al.
Published: (2024-07-01)

Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score
by: Zi-yi Zhu, et al.
Published: (2022-06-01)

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
by: Zhihong Tang, et al.
Published: (2024-06-01)

Vessels That Encapsulate Tumor Clusters (VETC) Predict cTACE Response in Hepatocellular Carcinoma
by: Lin C, et al.
Published: (2023-03-01)

Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma
by: Yashwant Patidar, et al.
Published: (2019-04-01)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
by: Liang Yin, et al.
Published: (2023-05-01)

Prognostic Role of Lymphocyte-to-Monocyte Ratio (LMR) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Undergoing Chemoembolizations (DEM-TACE or cTACE) of the Liver: Exploring the Link between Tumor Microenvironment and Interventional Radiology
by: Roberto Minici, et al.
Published: (2024-06-01)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
by: Zhao Wu, et al.
Published: (2023-04-01)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
by: Pierleone Lucatelli, et al.
Published: (2021-02-01)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
by: Dominik Bettinger, et al.
Published: (2018-08-01)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
by: Pierleone Lucatelli, et al.
Published: (2021-07-01)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-10-01)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
by: Li Chen, et al.
Published: (2021-03-01)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
by: Simon Bernatz, et al.
Published: (2023-01-01)

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
by: Junxiao Wang, et al.
Published: (2023-01-01)

Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails
by: Guoliang Wang, et al.
Published: (2024-06-01)

Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the Treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study
by: Long Hai MD, et al.
Published: (2024-05-01)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
by: Biao Yang, et al.
Published: (2021-12-01)

A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE
by: Jiang B, et al.
Published: (2024-07-01)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
by: Yejing Zhu, et al.
Published: (2023-01-01)

Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
by: Ziqiang Han, et al.
Published: (2022-12-01)

The efficacy and safety of modified DEB-TACE in the treatment of unresectable large hypervascular hepatocellular carcinoma
by: LIU Song, LI Long, WANG Qingdong, YU Guangji
Published: (2024-11-01)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
by: Yonghua Bi, et al.
Published: (2023-02-01)

Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
by: Zhang Xuexian, et al.
Published: (2024-10-01)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
by: Wei Huang, et al.
Published: (2022-08-01)

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
by: Shuping Qu, et al.
Published: (2022-04-01)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
by: Wenzhe Fan, et al.
Published: (2023-01-01)

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis
by: Qiu Z, et al.
Published: (2019-11-01)

Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose?
by: Maria Adriana Cocozza, et al.
Published: (2023-10-01)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
by: Wei‐Jun Wang, et al.
Published: (2023-05-01)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
by: Cyrille Féray, et al.
Published: (2023-04-01)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
by: Jung Hee Kim, et al.
Published: (2017-03-01)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
by: Zhanwang Xiang MD, et al.
Published: (2023-09-01)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
by: Maximilian N. Kinzler, et al.
Published: (2023-03-01)

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
by: Baojiang Liu, et al.
Published: (2023-08-01)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
by: Fei Cao, et al.
Published: (2021-12-01)

Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Similar Items

Similar Items